Karn Wijarnpreecha MD MPH

Hepatology & Liver Transplantation

Clinical Associate Professor/Transplant hepatologist

Summary

Dr. Karn Wijarnpreecha is a transplant hepatologist and gastroenterologist based in Phoenix, AZ. He completed his medical education at Chiang Mai University, followed by residency in internal medicine at Bassett Medical Center, and fellowships in gastroenterology, hepatology, and transplant hepatology at the Mayo Clinic College of Medicine and University of Michigan, respectively. Dr. Wijarnpreecha serves as a Clinical Associate Professor at the University of Arizona College of Medicine and as a Transplant Hepatologist at Banner - University Medical Center Phoenix. His research experience includes hepatology, steatotic liver disease, metabolic dysfunction-associated steatotic liver disease, and alcohol-related liver disease, with numerous publications in peer-reviewed journals. He has been recognized with several awards, including the AASLD Emerging Liver Scholar Mentor and Faculty Clinical Investigator of the Year in 2024.

University of MichiganFellowship, Transplant Hepatology, 2021 - 2022
Johns Hopkins Bloomberg School of Public HealthM.P.H., 2019 - 2021
Mayo Clinic College of MedicineM.D., Gastroenterology and Hepatology, 2018 - 2021
Bassett Medical CenterM.D., Internal Medicine Resident, 2015 - 2018
Chiang Mai UniversityM.D., Medicine, Second Class Honor, 2007 - 2013

AASLD Emerging Liver Scholar Mentor AASLD, 2024-2025
Faculty Appreciation Award University of Arizona College of Medicine - Phoenix, 2024
Faculty Clinical Investigator of the Year Banner University Medical Center Phoenix, 2024

PubMed

SGLT-2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes.
Do Han Kim, Donghyun Ko, Vincent L Chen, Jose A Porres, Carlos Elizondo Alatorre
Liver International. 2026-02-01
Imaging Based Modalities for Identifying "At Risk" MASH. A Diagnostic Test Meta-analysis.
Shyna Zhuoying Gunalan, Michelle Shi Ni Law, Yi Xin Kua, Zhenning Yu, Ryan Yan Zhe Lim
The American Journal of Gastroenterology. 2026-01-13
Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries.
Pojsakorn Danpanichkul, Yanfang Pang, Primrose Tothanarungroj, Disatorn Dejvajara, Donghee Kim
Cancer. 2026-01-01

Journal Articles

The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019
Pojsakorn Danpanichkul, Siwanart Kongarin , Sarunpakorn Permpatdechakul , Natchaya Polpichai, Kwanjit Duangsonk, Worapaka Manosroi , Nathorn Chaiyakunapruk, Omar Y Mou..., J Clin Med ., 10/27/2023
Antineutrophil Cytoplasmic Autoantibodies-Associated Vasculitides and Risk of Stroke: A Systematic Review and Meta-analysis
Patompong Ungprasert, Karn Wijarnpreecha, Siroj Dejhansathit, Wisit Cheungpasitporn, Neurol India, 10/10/2022
Body fat distribution: a crucial target for intervention in nonalcoholic fatty liver disease and fibrosis
Karn Wijarnpreecha 1 2, Aijaz Ahmed 3, Donghee Kim 3, Hepatobiliary Surg Nutr, 10/2022

SGLT2 Inhibition Promising for Patients with Cirrhosis and on DiureticsSeptember 4th, 2025
More Cardiovascular Disease Found in Lean People with Non-Alcoholic Fatty Liver Disease Than in Those Who Are Overweight with the Same ConditionMay 13th, 2022
The Association of Weight Gain with Nonalcoholic Fatty Liver Disease and Fibrosis Detected by FibroScan in the United StatesJanuary 15th, 2022

Chair, AASLD Membership and Mentorship Special Interest Group 2019 - Present
Subcommittee Leadership, AASLD Public Health/Health Care Delivery Special Interest Group 2018 - Present
alumni board, Bassett alumni board 2018 - Present